Octagon Capital Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Octagon Capital Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$39.6M	Hold	8,859,911	–	–	4.38%	7
2025 Q4	$48.7M	Sell	8,859,911 -207,589	-2%	-$1.01M	5.92%	4
2025 Q3	$29.7M	Sell	9,067,500 -3,525,000	-28%	-$9.98M	4.49%	7
2025 Q2	$29.1M	Buy	12,592,500 +1,892,500	+18%	+$4.11M	6.38%	4
2025 Q1	$14.9M	Buy	10,700,000 +250,000	+2%	+$418K	2.88%	12
2024 Q4	$18.1M	Buy	10,450,000 +5,877,778	+129%	+$12.2M	2.97%	12
2024 Q3	$9.19M	Hold	4,572,222	–	–	1.43%	19
2024 Q2	$10.2M	Buy	4,572,222 +1,542,222	+51%	+$4.49M	1.61%	17
2024 Q1	$8.7M	Buy	+3,030,000	New	+$6.31M	1.04%	28
2023 Q4	–	Sell	-2,777,778	Closed	-$8.78M	–	45
2023 Q3	$8.78M	Buy	+2,777,778	New	+$5.19M	1.35%	18
2021 Q3	–	Sell	-320,440	Closed	-$6.79M	–	35
2021 Q2	$6.79M	Hold	320,440	–	–	1.41%	20
2021 Q1	$6.5M	Hold	320,440	–	–	2.45%	17
2020 Q4	$8.5M	Buy	+320,440	New	+$6.9M	2.95%	14

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Octagon Capital Advisors's TSHA Position: Q1 2026 in Review

Octagon Capital Advisors held its Taysha Gene Therapies (TSHA) position steady in Q1 2026 at 8,859,911 shares worth $39.6M. The position accounts for 4.38% of the portfolio, ranked #7.

Octagon Capital Advisors first reported a position in TSHA in Q4 2020 and has held it in 13 quarters since. The position peaked at $48.7M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

Octagon Capital Advisors held 8,859,911 shares of Taysha Gene Therapies worth $39.6M as of Q1 2026.
Octagon Capital Advisors left its Taysha Gene Therapies share count unchanged in Q1 2026.
Taysha Gene Therapies made up 4.38% of Octagon Capital Advisors's portfolio in Q1 2026, its #7 holding.
Octagon Capital Advisors first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 13 quarters since.
Octagon Capital Advisors's Taysha Gene Therapies position peaked at $48.7M in Q4 2025.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.